Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China

Trial Profile

An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 01 Oct 2018 Planned primary completion date changed from 31 Dec 2018 to 26 Nov 2018.
    • 26 Jul 2018 Planned End Date changed from 19 Dec 2019 to 19 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top